-
Update your clinical practice; make your plans now for the following 2010 conferences:
-
Women in the United States now account for more than one-quarter of all new HIV/AIDS diagnoses.
-
Good news for patients at your clinic: The second-generation FC2 Female Condom is available for purchase in the United States, which gives American women a nonlatex, female-controlled option in disease protection.
-
In 2007, the Centers for Disease Control and Prevention reported that 26% of HIV/AIDS diagnoses among adolescents and adults were among females.
-
Family planning clinicians have new research information to add to their emergency contraception (EC) knowledge bank as they incorporate use of two new branded products into their practice.
-
Research of an experimental urine test indicates that it successfully diagnoses chlamydia infection in men within the hour, which improves the ability to successfully treat the infection on the spot and prevent retransmission.
-
Get set for possible changes in human papillomavirus (HPV) vaccine use. A Food and Drug Administration (FDA) review committee has voted that clinical data support the efficacy and safety of GlaxoSmithKline's Cervarix vaccine candidate for the prevention of cervical precancers and cervical cancer related to HPV types 16 and 18 in girls and young women.
-
In July 2009, data from the National Vital Statistics System were published presenting a snapshot of the sexual and reproductive health of young people aged 10-24 between 2002 and 2007.
-
Despite the findings of two new studies,1,2 providers should focus on the fact that two earlier, large studies have compared safety data from women using Yasmin (Bayer HealthCare Pharmaceuticals; Wayne, NJ) to that of other oral contraceptive (OC) users,3,4 family planning experts emphasize.
-
After taking the necessary diagnostic steps, the results are clear: The patient sitting in front of you needs to be treated for bacterial vaginosis (BV). The most common vaginal infection in women of childbearing age, women with BV may present with a white or gray discharge, odor, pain, or burning during urination. Symptoms aren't always present, though. More than 50% of women with BV may be asymptomatic.